General Information of Drug (ID: DM69NF1)

Drug Name
EP-101 Drug Info
Synonyms
106-86-5; 1,2-Epoxy-4-vinylcyclohexane; 3-Vinyl-7-oxabicyclo[4.1.0]heptane; Epoxide 101; 4-Vinylcyclohexene oxide; Unoxat epoxide 101; Vinylcyclohexane monoxide; 4-Vinyl-1,2-epoxycyclohexane; 1-Vinyl-3,4-epoxycyclohexane; 4-Vinylcyclohexene monoxide; 3,4-Epoxycyclohexylethylene; 7-Oxabicyclo[4.1.0]heptane, 3-ethenyl-; 4-Vinylcyclohexane monoepoxide; EP-101; Vinylcyclohexene monoxide; 4-Vinylcyclohexene-1,2-epoxide; 4-Vinylcyclohexane, 1,2-epoxide; EINECS 203-436-1; 4-Vinyl-1-Cyclohexene 1,2-Epoxide; NSC 35409
Indication
Disease Entry ICD 11 Status REF
Chronic obstructive pulmonary disease CA22 Phase 2 [1]
Breast cancer 2C60-2C65 Phase 1 [2]
Cross-matching ID
PubChem CID
7832
CAS Number
CAS 106-86-5
TTD Drug ID
DM69NF1

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Acetylcholine DMDF79Z Cataract 9B10 Approved [4]
Tiotropium DMFDC0Q Chronic obstructive pulmonary disease CA22 Approved [5]
Darifenacin DMWXLYZ Overactive bladder GC50.0 Approved [6]
Methylscopolamine DM5VWOB Peptic ulcer DA61 Approved [7]
Clidinium DMUMQZ0 Abdominal stomach pain DD91.4 Approved [8]
Oxybutynin hydrochloride DMF2KLU Urinary incontinence MF50.2 Approved [9]
Incruse Ellipta DM32GSJ Chronic obstructive pulmonary disease CA22 Approved [10]
Revefenacin DMMP5SI Chronic obstructive pulmonary disease CA22 Approved [11]
Scopolamine DMOM8AL Addictive disorder 6C50-6C5Z Approved [12]
Isopropamide iodide DMQYV60 Allergic rhinitis CA08.0 Approved [13]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Muscarinic acetylcholine receptor (CHRM) TTOXS3C NOUNIPROTAC Antagonist [3]

References

1 ClinicalTrials.gov (NCT01426009) Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101 in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Long-acting muscarinic receptor antagonists for the treatment of respiratory disease. Pulm Pharmacol Ther. 2013 Jun;26(3):307-17.
4 Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors: receptor subtype selectivity via cooperativity rather than affinity. Mol Pharmacol. 2004 Jan;65(1):257-66.
5 Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. J Pharmacol Exp Ther. 2013 May;345(2):260-70.
6 Characterisation of [3H]-darifenacin as a novel radioligand for the study of muscarinic M3 receptors. J Recept Signal Transduct Res. 1997 Jan-May;17(1-3):177-84.
7 Lithocholylcholine, a bile acid/acetylcholine hybrid, is a muscarinic receptor antagonist. J Pharmacol Exp Ther. 2002 Oct;303(1):29-35.
8 Pharmacological comparison of the cloned human and rat M2 muscarinic receptor genes expressed in the murine fibroblast (B82) cell line. J Pharmacol Exp Ther. 1998 Feb;284(2):500-7.
9 Effects of propiverine hydrochloride (propiverine) on the muscarinic receptor binding affinity in guinea pig tissues and on salivation in conscious dogs. Nihon Yakurigaku Zasshi. 1999 Mar;113(3):157-66.
10 Clinical pipeline report, company report or official report of GlaxoSmithKline.
11 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
12 The amygdala modulates morphine-induced state-dependent memory retrieval via muscarinic acetylcholine receptors. Neuroscience. 2009 May 5;160(2):255-63.
13 Competitive and non-competitive antagonism exhibited by 'selective' antagonists at atrial and ileal muscarinic receptor subtypes. Br J Pharmacol. 1987 Apr;90(4):701-7.